Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.45 |
| ▸ | MMP9 | P14780 | 17/20 | 0.45 |
| ▸ | MMP3 | P08254 | 3/20 | 0.45 |
| ▸ | MMP13 | P45452 | 3/20 | 0.45 |
| ▸ | MMP1 | P03956 | 3/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.43 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.42 |
| ▸ | MMP14 | P50281 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7860511 | 0.88 | MMP2 (0.47) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL8482551 | 0.85 | MMP2 (0.52) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7861855 | 0.83 | MMP2 (0.44) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL10021381 | 0.83 | MMP2 (0.50) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7862695 | 0.83 | MMP2 (0.50) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL8480599 | 0.82 | MMP2 (0.48) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7860408 | 0.82 | MMP2 (0.51) | MMP2MMP9MMP3MMP13 | |
| SCHEMBL7865130 | 0.82 | MMP2 (0.51) | MMP2MMP9MMP3MMP13 | |
| SCHEMBL7865124 | 0.81 | TSHR (0.58) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7861661 | 0.80 | NPC1 (0.62) | MMP2MMP9MMP3MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0923529-B1 | SUBSTITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER AG (US) | 2001-09-19 | — | — | EP | claimed |
| EP-0923529-A1 | SUBSITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | Bayer Corporation (US) | 1999-06-23 | — | — | EP | claimed |
| WO-1997043237-A1 | SUBSITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER CORPORATION (US) | 1997-11-20 | — | — | WO | claimed |
| EP-0923529-B1 | SUBSTITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER AG (US) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000056283-A1 | INHIBITION OF MATRIX METALLOPROTEINASES WITH POLYMERS AND PHARMACEUTICAL APPLICATIONS THEREOF | THE B.F.GOODRICH COMPANY (US) | 2000-09-28 | — | — | WO | disclosed |
| EP-0923529-A1 | SUBSITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | Bayer Corporation (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5863915-A | ENZYME INHIBITORS FOR BONES AND JOINTS | BAYER CORPORATION (US) | 1999-01-26 | — | — | US | disclosed |
| WO-1997043237-A1 | SUBSITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |